WO2001036685A3 - Differential gene expression in cancer - Google Patents

Differential gene expression in cancer Download PDF

Info

Publication number
WO2001036685A3
WO2001036685A3 PCT/US2000/031809 US0031809W WO0136685A3 WO 2001036685 A3 WO2001036685 A3 WO 2001036685A3 US 0031809 W US0031809 W US 0031809W WO 0136685 A3 WO0136685 A3 WO 0136685A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene expression
differential gene
methods
glioblastoma
Prior art date
Application number
PCT/US2000/031809
Other languages
French (fr)
Other versions
WO2001036685A2 (en
Inventor
Roger A Kroes
Joseph R Moskal
Hirotaka Yamamoto
Original Assignee
Nyxis Neurotherapies Inc
Roger A Kroes
Joseph R Moskal
Hirotaka Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyxis Neurotherapies Inc, Roger A Kroes, Joseph R Moskal, Hirotaka Yamamoto filed Critical Nyxis Neurotherapies Inc
Priority to AU19223/01A priority Critical patent/AU1922301A/en
Publication of WO2001036685A2 publication Critical patent/WO2001036685A2/en
Publication of WO2001036685A3 publication Critical patent/WO2001036685A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention is directed towards methods for ascertaining gene expression characteristic for cancer, in particular brain cancers such as glioblastoma, and the sequences identified thereby. Compositions, methods and kits encompassing such are provided herein.
PCT/US2000/031809 1999-11-17 2000-11-17 Differential gene expression in cancer WO2001036685A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19223/01A AU1922301A (en) 1999-11-17 2000-11-17 Differential gene expression in cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16610699P 1999-11-17 1999-11-17
US16605699P 1999-11-17 1999-11-17
US60/166,106 1999-11-17
US60/166,056 1999-11-17

Publications (2)

Publication Number Publication Date
WO2001036685A2 WO2001036685A2 (en) 2001-05-25
WO2001036685A3 true WO2001036685A3 (en) 2002-01-10

Family

ID=26861932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031809 WO2001036685A2 (en) 1999-11-17 2000-11-17 Differential gene expression in cancer

Country Status (2)

Country Link
AU (1) AU1922301A (en)
WO (1) WO2001036685A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167314B2 (en) 2009-10-05 2019-01-01 Northwestern University Methods of treating depression and other related diseases

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020142957A1 (en) * 2000-08-07 2002-10-03 Hepler William T. Compositions and methods for the therapy and diagnosis of colon cancer
NZ543751A (en) 2003-05-23 2008-05-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumors of glial origin
CN101336300A (en) * 2005-12-16 2008-12-31 健泰科生物技术公司 Method for diagnosing, prognosing and treating glioma
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
BR112012020142A2 (en) 2010-02-11 2020-08-18 Northwestern University nmda receptor modulators with stabilized secondary structure and their uses.
US8747530B2 (en) 2011-02-15 2014-06-10 Lta Corporation Systems for water extraction from air
KR20150110784A (en) 2013-01-29 2015-10-02 노렉스, 인크. Spiro-lactam nmda receptor modulators and uses thereof
BR112015018087B1 (en) 2013-01-29 2022-09-20 Aptinyx Inc SPIRO-LACTAMA N-METHYL-D-ASPARTATE (NMDA) RECEPTOR MODULATING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF
JP2016506961A (en) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. Spirolactam NMDA receptor modulator and use thereof
EA031905B1 (en) 2013-01-29 2019-03-29 Аптиникс Инк. Spiro-lactam nmda receptor modulators and use thereof
JP6531042B2 (en) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド Spirolactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (en) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
ES2972533T3 (en) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam-based NMDA receptor modulators and their uses
KR102462288B1 (en) 2016-08-01 2022-11-01 앱티닉스 인크. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
CN109937204B (en) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
ES2973283T3 (en) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam NMDA receptor modulators and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
BR112020015710A2 (en) 2018-01-31 2020-12-08 Aptinyx Inc. SPIRAL-LACTAM MODULATORS OF NMDA RECEPTORS AND USES OF THE SAME
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
US5858712A (en) * 1997-02-06 1999-01-12 Incyte Pharmaceuticals, Inc. CDNA encoding a LEA-motif developmental protein homologous to avian px19
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
WO1999023252A1 (en) * 1997-11-05 1999-05-14 Isis Innovation Limited Cancer gene
WO1999024469A1 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999053062A2 (en) * 1998-04-16 1999-10-21 Cedars-Sinai Health System, Et Al Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858712A (en) * 1997-02-06 1999-01-12 Incyte Pharmaceuticals, Inc. CDNA encoding a LEA-motif developmental protein homologous to avian px19
WO1998053319A2 (en) * 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
WO1999022243A1 (en) * 1997-10-24 1999-05-06 Human Genome Sciences, Inc. 148 human secreted proteins
WO1999023252A1 (en) * 1997-11-05 1999-05-14 Isis Innovation Limited Cancer gene
WO1999024469A1 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999053062A2 (en) * 1998-04-16 1999-10-21 Cedars-Sinai Health System, Et Al Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] EMBL; 12 April 1997 (1997-04-12), STRAUSBERG R. ET AL: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor gene index", XP002181163, Database accession no. EM_EST:HS1191117 *
DATABASE EBI [online] EMBL; 27 April 1997 (1997-04-27), ADAMS M.D. ET AL: "Use of a random BAC End Sequence Database for Sequence-Ready Map Building", XP002181161, Database accession no. EM_GSS:AQ005923 *
DATABASE EBI [online] EMBL; 27 July 1999 (1999-07-27), AGOSTINO M.J. ET AL: "SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM", XP002181162, Database accession no. GSN:AAX60579 *
DATABASE EBI [online] EMBL; 5 January 1998 (1998-01-05), HILLIER ET AL: "WashU-NCI human EST Project", XP002174758, Database accession no. EM_EST:AA705392 *
LAL ANITA ET AL: "A public database for gene expression in human cancers.", CANCER RESEARCH, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5403 - 5407, XP002174720, ISSN: 0008-5472 *
YAMAGUCHI FUMIO ET AL: "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 2, 1994, 1994, pages 484 - 488, XP002141422, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167314B2 (en) 2009-10-05 2019-01-01 Northwestern University Methods of treating depression and other related diseases

Also Published As

Publication number Publication date
WO2001036685A2 (en) 2001-05-25
AU1922301A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2001036685A3 (en) Differential gene expression in cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO2005017207A3 (en) Methods and compositions for detecting colon cancers
WO2003031932A3 (en) Methods and compositions for detecting colon cancers
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2003012067A3 (en) Expression profile of prostate cancer
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006020947A9 (en) Phosphonate fluorescent dyes and conjugates
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
WO2000066528A3 (en) Quinones for treatment of diseases
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
EP1007553A4 (en) Zonula occludens toxin receptors
WO2004031402A3 (en) Methylation profile of cancer
WO2005000204A3 (en) Pancreatic cancer treatment
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2003035889A3 (en) Compositions and methods for bacteria detection
WO2004091484A3 (en) Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase